Connect with us

Hi, what are you looking for?

Wednesday, May 18, 2022
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.

The weed wire

Medical Marijuana reports first-ever positive adjusted EBITDA

Company revenue rose 26% year-over-year to US$75 million

American penny stock company Medical Marijuana, Inc. (OTC: MNJA) reported rapid sales growth in their year-end financial results for the period ended Dec. 31, 2019.

Net revenue was up year-over-year by 26 per cent, the company said in a Wednesday press release, bringing in $75.6 million, with a gross margin of 76.4 per cent for 2019. In 2018 the company brought in a net revenue of US$59.8 million.

The company also raised its net income to US$3.3 million, up from a loss of US$8 million for the previous year. Also moving from the negatives was the company’s adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA), reported at US$139,000 compared to a loss of US$1.2 million in 2018.

Read more: Cresco Labs drops double digits on sizable Q4 loss

Medical Marijuana was the first cannabis business to be publicly traded in the United States, and was also the first business to secure CBD import permits from the governments of Brazil, Mexico, Argentina and Paraguay, according to the company.

International operations have thrived in European and Latin American markets and the company is pushing to expand into Asia next, company COO Blake Schroeder said in a statement.

“We hope that these efforts will continue to build shareholder value and help bring our industry-leading products to broader audiences worldwide,” Schroeder said.

International and domestic growth is thanks to a successful strategic plan, CEO Stuart Titus said.

“In 2019, Medical Marijuana, Inc. and its subsidiaries continued to execute on our strategic growth and fiscal responsibility action plan that rendered our best results yet and I could not be more excited to share them with shareholders,” Titus said. “We were able to not only generate increased revenues but focus on our bottom line by making strategic adjustments to expenditures.”

Operating under the 2018 Farm Bill, the company makes CBD-infused food, produces CBD products and has a cannabinoid-based clinical research centre. It also has the long-term goal of growing its subsidiaries Kannaway and HempMeds into a distribution business.

Medical Marijuana stock sits at US$0.014 per share and has been trending downwards since Christmas, when the common share halved in value from US$0.02 per share.

Top image by Darrin Harris Frisby via Drug Policy Alliance

 

michelle@mugglehead.com

@missmishelle

1 Comment

1 Comment

  1. cbd website

    October 10, 2020 at 2:48 pm

    Sharing this with sick uncle.

Leave a Reply

Your email address will not be published.

You May Also Like

Health and Safety

Science doesn't know yet, but one psychedelic researcher is chasing clues to see if it can

Canada

As more medium-to-small producers came into play this year, great weed started hitting legal shelves at fairer prices

Culture

Punishments for possession include caning and the death penalty. Despite a global trend of reform, The Fine City remains staunch in its anti-drug stance

Analysis

While legal weed businesses decry enforcement of their accounts, the platform says it's keeping its all-ages community safe